David A. Roth
GlaxoSmithKline (United States) · 168 works · 23,709 citations · h-index 44
Top works
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
- Sequential Therapies for Proliferative Lupus Nephritis
- The evaluation of renal transplantation candidates: clinical practice guidelines.
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
- POSTTRANSPLANT HYPERGLYCEMIA
- AIDS-related glomerulopathy: Occurrence in specific risk groups
- Hepatitis C virus: The nephrologist's view
- Delayed function reduces renal allograft survival independent of acute rejection
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
- Recipient body size and cadaveric renal allograft survival.
- Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
- A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
- Management of the Waiting List for Cadaveric Kidney Transplants
- A PROSPECTIVE STUDY OF HEPATITIS C VIRUS INFECTION IN RENAL ALLOGRAFT RECIPIENTS1, 2
- Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
- A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
- OP0232 Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE
- Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII
- Lupus nephritis: a clinical review for practicing nephrologists